Wegovy to Ozempic Dose Conversion: Why the Numbers Don't Simply Swap

Step 1: Understand what you're actually comparing

Semaglutide works the same way whether it is dispensed as Wegovy or Ozempic. It activates GLP-1 receptors, slows digestion, and reduces appetite. Because the molecule is identical, it is easy to assume the doses must translate directly. They do not, and the reason is rooted in how each medicine was developed and licensed, not in the chemistry.

Wegovy was trialled and approved specifically for weight management. Its dose schedule runs from 0.25 mg up to a 2.4 mg weekly maintenance dose, with each step designed to give the body time to adjust. The full Wegovy dose schedule is built around tolerability as much as efficacy. Ozempic, by contrast, was developed and licensed for blood glucose control in type 2 diabetes. Its maximum licensed dose in the UK is 1 mg weekly in most cases, with 2 mg used in specific diabetes management scenarios under prescriber direction. The two products were never designed to map onto each other. If you have been on Wegovy 1.7 mg or 2.4 mg, there is simply no corresponding Ozempic dose that sits in the same therapeutic range for weight management, because Ozempic was never approved to go there for that purpose.

Checking your current pen's label takes under a minute and is worth doing before any conversation with a prescriber, it tells you exactly which medicine, which strength, and which manufacturer's instructions apply to you right now.

Step 2: Understand the UK licensing position clearly

The MHRA has been direct on this point. The NHS semaglutide medicines page explains that Wegovy is the licensed weight-management form of semaglutide, while Ozempic is licensed solely for type 2 diabetes. Using Ozempic as a weight-loss medicine in the UK means using it outside its authorised indication. That is not the same as saying it is illegal (prescribers can use medicines off-label in specific clinical circumstances) but it means the prescriber carries additional clinical and medico-legal responsibility, that the evidence base used to approve it does not cover weight loss, and that you as a patient would not be following a treatment pathway that regulators have assessed for that purpose.

For a fuller look at the Ozempic semaglutide licence and what the doses mean in a diabetes context, our guide to Ozempic semaglutide dosing covers the approved schedule in detail. The MHRA's own guidance makes clear that GLP-1 medicines were not assessed for cosmetic or general weight loss outside their specific licensed indications.

This matters practically: if you are currently on Wegovy for weight management and someone suggests switching you to Ozempic without a full clinical review, that is a signal to ask more questions, not to proceed quietly.

Step 3: Know what a prescriber actually considers before any switch

When a clinician considers moving a patient from one semaglutide product to another, several things are weighed together. First, the reason for switching. Supply interruptions, cost pressure, and changes in clinical need are all different situations that lead to different answers. Second, the current dose. A patient stable on Wegovy 2.4 mg cannot simply carry that dose across; there is no 2.4 mg Ozempic to move to, and starting a lower dose after months at a higher one is a clinical decision with real implications for treatment progress. Weight changes when dropping below your maintenance dose are a real concern some patients experience.

Third, the reason you are taking semaglutide matters. If you do not have type 2 diabetes, a diabetes-licensed medicine is not the natural clinical fit. A prescriber who understands your full picture (including any other medicines you take and your weight-management history) is the only person placed to advise on switching safely. If you are also curious about how a switch from a different GLP-1 entirely compares, the liraglutide-to-semaglutide conversion involves a similar set of clinical considerations and equally cannot be handled with a chart alone.

What IS licensed for weight management in the UK right now

If you are looking for a semaglutide-based weight-loss treatment in the UK, Wegovy is the one to consider. It is the only form of semaglutide with MHRA authorisation for that purpose, and it has a clear dose pathway up to 2.4 mg weekly. A newer option, the Wegovy tablet, received MHRA approval in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. Our Wegovy overview covers both the injection and tablet options in full.

Tirzepatide (Mounjaro) is the other UK-licensed weight-management injection. It works on both GLP-1 and GIP receptors and, in clinical trials, produced greater average weight reduction than semaglutide 2.4 mg in head-to-head data from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025. Both medicines require a prescription following clinical assessment. Speak to our prescribers if you would like a clinician to review which option suits your situation, it costs nothing to start that conversation, and there is no pressure to proceed.

For context on costs across different providers, the Wegovy price comparison page explains what a legitimate private price typically includes and why the headline figure is rarely the whole story.